HHS purchases IV antiviral drug to treat monkeypox
The Department of Health and Human Services this week purchased $26 million worth of intravenous TPOXX (tecovirimat) to treat monkeypox, which the manufacturer expects to deliver next year. Under its contract with SIGA Technologies, HHS may still purchase additional oral and IV TPOXX, an antiviral drug approved by the Food and Drug Administration to treat smallpox and available under an investigational protocol to treat monkeypox. TPOXX is available free to states and territories through the Strategic National Stockpile, which held over 1.7 million treatment courses before the monkeypox outbreak. HHS last week declared the U.S. outbreak, which exceeds 10,000 cases, a public health emergency.
Related News Articles
Headline
The Centers for Disease Control and Prevention announced Dec. 16 that it adopted individual-based decision-making for parents deciding whether to give the…
Headline
The Centers for Disease Control and Prevention issued an advisory Dec. 3 on an outbreak of Marburg virus in Ethiopia. The agency said a risk of spread to the U…
Headline
A Washington resident recently hospitalized with the H5N5 strain of bird flu died Nov. 21, according to the Washington State Department of Health. The…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Washington State Department of Health announced Nov. 14 that a state resident hospitalized earlier this month is the first human to have the H5N5 strain of…
Headline
There have been 1,681 confirmed cases of measles in the U.S. so far this year, according to the latest Centers for Disease Control and Prevention data. Cases…